Cite
HARVARD Citation
Tye-Din, J. et al. (2023). Efficacy and safety of gluten peptide-based antigen-specific immunotherapy (Nexvax2) in adults with coeliac disease after bolus exposure to gluten (RESET CeD): an interim analysis of a terminated randomised, double-blind, placebo-controlled phase 2 study. Lancet gastroenterology and hepatology. pp. 446-457. [Online].